Castellano | Euskara | Français | English
DAR No 2: Sacubitril/Valsartan. Entresto-Neparvis® for heart failure
Share it
Useful for your heart if you use your head
- Sacubitril/Valsartan (SAC /VAL) is a fixed-dose combination of a neprilysin inhibitor and an ARB.
- SAC /VAL has been proven to provide clinical benefit in terms of morbidity and mortality in patients who experienced heart failure (HF) with ejection fraction ≤35% and increased BNP or NT-pro-BNP plasma levels which symptoms are not controlled with the optimal therapy recommended.
- Associated risks include: hypotension, hyperkalemia and angioedema. There is a potential risk for cognitive impairment in the long term.
- SAC /VAL must be only used in patients with similar characteristics to those of study patients, as its effectiveness and safety has only been demonstrated in this group of patients.
- Treatment/year cost per patient amounts to €2,520, 60-fold higher than enalapril.
